Investasi
Fitur
BiayaKeamanan
Akademi
Lainnya
Pluang+

Bandingkan Harga & Kinerja Equity Development Investment Tbk. (GSMF) vs Brigit Biofarmaka Teknologi Tbk. (OBAT)

Equity Development Investment Tbk.Trading
Brigit Biofarmaka Teknologi Tbk.Trading

Kinerja harga (24 Jam Terakhir)

Statistik utama

Perbedaan Equity Development Investment Tbk. dan Brigit Biofarmaka Teknologi Tbk.: Equity Development Investment Tbk. diperdagangkan di Rp106 (kapitalisasi pasar 1,92 T, volume 24 jam 294,19 jt), sedangkan Brigit Biofarmaka Teknologi Tbk. diperdagangkan di Rp240 (kapitalisasi pasar 166,01 M, volume 24 jam 324 rb). Perbedaan utamanya: Equity Development Investment Tbk. jauh lebih besar — sekitar 11,6× kapitalisasi pasar Brigit Biofarmaka Teknologi Tbk., dan Equity Development Investment Tbk. lebih aktif diperdagangkan (294,19 jt vs 324 rb). Mana yang lebih baik tergantung tujuan investasimu.

GSMFOBAT
Kapitalisasi Pasar
1,92 T166,01 M
Volume
294,19 jt324 rb
Lot
2,94 jt3,24 rb
Perputaran
36,95 M77,68 jt
Harga Rata-rata
125,58239,75
Nilai Transaksi
36,95 M77,68 jt
Harga Ekuilibrium Indikatif
106240
Volume Ekuilibrium Indikatif
8,47 rb1

Perbandingan imbal hasil

Imbal hasil berjalan pada periode standar

Berita terkini

Berita terbaru kedua aset

GSMF
Lihat detail
OBAT
Lihat detail

Tentang Equity Development Investment Tbk.

PT Equity Development Investment Tbk (the “Company”) was established in Jakarta under the name of PT Gajah Surya Arta Leasing on November 1, 1982 based on the Notarial Deed of Didi Sudjadi, S.H., No. 1, as amended by deed No. 30 dated March 6, 1985 of the same notary. The Company changed its name to be PT BDNI Capital Corporation Tbk. On February 7, 2001, it changed the named again to be PT GT Investama Kapital, Tbk.

Selengkapnya di halaman GSMF

Tentang Brigit Biofarmaka Teknologi Tbk.

PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.

Selengkapnya di halaman OBAT